Cargando…

Psoriasis Severity Assessment Combining Physician and Patient Reported Outcomes: The Optimal Psoriasis Assessment Tool

INTRODUCTION: Psoriasis Area Severity Index (PASI) assessment is complex and time-consuming. A simpler assessment measure more sensitive to changes in symptom severity and predictive of patients’ quality of life (Dermatology Life Quality Index, DLQI) is needed. This study aims to evaluate the Optima...

Descripción completa

Detalles Bibliográficos
Autores principales:	Leonardi, Craig, See, Kyoungah, Gallo, Gaia, McKean-Matthews, Missy, Zhang, Ying, Goldblum, Orin, Mallbris, Lotus, Burge, Russel
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2021
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8322262/ https://www.ncbi.nlm.nih.gov/pubmed/34047947 http://dx.doi.org/10.1007/s13555-021-00544-6

Ejemplares similares

Dynamic Visual Representation of Clinical Efficacy of Ixekizumab in Psoriasis
por: Hawkes, Jason E., et al.
Publicado: (2021)

Number Needed to Treat Network Meta-Analysis to Compare Biologic Drugs for Moderate-to-Severe Psoriasis
por: Leonardi, Craig L., et al.
Publicado: (2022)

Simultaneous Nail and Skin Clearance in Ixekizumab Head-to-Head Trials for Moderate-to-Severe Psoriasis and Psoriatic Arthritis
por: Elewski, Boni E., et al.
Publicado: (2022)

Injection Site Reactions in the Federal Adverse Event Reporting System (FAERS) Post-Marketing Database Vary Among Biologics Approved to Treat Moderate-To-Severe Psoriasis
por: Grace, Elsie, et al.
Publicado: (2019)

Epidemiology of psoriasis in hard-to-treat body locations: data from the Danish skin cohort
por: Egeberg, Alexander, et al.
Publicado: (2020)

The Physician Global Assessment and Body Surface Area composite tool is a simple alternative to the Psoriasis Area and Severity Index for assessment of psoriasis: post hoc analysis from PRISTINE and PRESTA
por: Walsh, Jessica A, et al.
Publicado: (2018)

Rapid Response of Biologic Treatments of Moderate-to-Severe Plaque Psoriasis: A Comprehensive Investigation Using Bayesian and Frequentist Network Meta-analyses
por: Warren, Richard B., et al.
Publicado: (2019)

A multi-item Physician Global Assessment scale to assess psoriasis disease severity: validation based on four phase III tofacitinib studies
por: Callis Duffin, Kristina, et al.
Publicado: (2019)

Risk of respiratory infection in patients with plaque psoriasis
por: Svedbom, Axel, et al.
Publicado: (2021)

Clinical outcomes at 1 year in early Psoriasis Area and Severity Index responders compared with non‐responders: Subgroup analysis of UNCOVER‐3 trial
por: Rosmarin, D., et al.
Publicado: (2021)

Comparison of Real-World Treatment Patterns Among Psoriasis Patients Treated with Ixekizumab or Adalimumab
por: Blauvelt, Andrew, et al.
Publicado: (2020)

Real-world health outcomes in adults with moderate-to-severe psoriasis in the United States: a population study using electronic health records to examine patient-perceived treatment effectiveness, medication use, and healthcare resource utilization
por: Armstrong, April W., et al.
Publicado: (2018)

The Development of the Genital Psoriasis Sexual Frequency Questionnaire (GenPs-SFQ) to Assess the Impact of Genital Psoriasis on Sexual Health
por: Gottlieb, Alice B., et al.
Publicado: (2017)

The Development of a Patient-Reported Outcome Measure for Assessment of Genital Psoriasis Symptoms: The Genital Psoriasis Symptoms Scale (GPSS)
por: Gottlieb, Alice B., et al.
Publicado: (2017)

HLA-Cw*0602 associates with a twofold higher prevalence of positive streptococcal throat swab at the onset of psoriasis: a case control study
por: Mallbris, Lotus, et al.
Publicado: (2009)

Ixekizumab provides persistent improvements in health‐related quality of life and the sexual impact associated with moderate‐to‐severe genital psoriasis in adult patients during a 52‐week, randomised, placebo‐controlled, phase 3 clinical trial
por: Ryan, C., et al.
Publicado: (2021)

Employment is maintained and sick days decreased in psoriasis/psoriatic arthritis patients with etanercept treatment
por: Boggs, Robert L, et al.
Publicado: (2014)

A Retrospective Cohort Analysis of Treatment Patterns Over 1 Year in Patients with Psoriasis Treated with Ixekizumab or Guselkumab
por: Blauvelt, Andrew, et al.
Publicado: (2022)

Drug survival of ixekizumab, TNF inhibitors, and other IL‐17 inhibitors in real‐world patients with psoriasis: The Corrona Psoriasis Registry
por: Lockshin, Benjamin, et al.
Publicado: (2021)

Treatment Goals for Psoriasis as Measured by Patient Benefit Index: Results of a National Psoriasis Foundation Survey
por: Armstrong, April, et al.
Publicado: (2022)

Continuous dosing versus interrupted therapy with ixekizumab: an integrated analysis of two phase 3 trials in psoriasis
por: Blauvelt, A., et al.
Publicado: (2017)

Disease Assessment in Psoriasis
por: Manchanda, Yashpal, et al.
Publicado: (2023)

Is Clear Always Clear? Comparison of Psoriasis Area and Severity Index (PASI) and the Physician’s Global Assessment (PGA) in Psoriasis Clearance
por: Wu, Albert G., et al.
Publicado: (2020)

Cumulative Clinical Benefits of Biologics in the Treatment of Patients with Moderate-to-Severe Psoriasis over 1 Year: a Network Meta-Analysis
por: Blauvelt, Andrew, et al.
Publicado: (2022)

Physician perspectives in the management of psoriasis and psoriatic arthritis: results from the population‐based Multinational Assessment of Psoriasis and Psoriatic Arthritis survey
por: van de Kerkhof, P.C.M., et al.
Publicado: (2015)

Real-World Biologic Adherence, Persistence, and Monotherapy Comparisons in US Patients with Psoriasis: Results from IBM MarketScan(®) Databases
por: Leonardi, Craig, et al.
Publicado: (2022)

Outcomes of Biologic Use in Asian Compared with Non-Hispanic White Adult Psoriasis Patients from the CorEvitas Psoriasis Registry
por: Yu, Chen, et al.
Publicado: (2022)

Optimization of psoriasis assessment system based on patch images
por: Moon, Cho-I., et al.
Publicado: (2021)

Psoriasis: A Primer for General Physicians
por: Dasari, Shalini, et al.
Publicado: (2023)

An Assessment of the Cost-Utility of Therapy for Psoriasis
por: Weiss, Stefan C, et al.
Publicado: (2006)

Echocardiographic and electrocardiographic assessments in patients with psoriasis
por: Aryanian, Zeinab, et al.
Publicado: (2021)

Efficacy and Safety of Ixekizumab Through 5 Years in Moderate-to-Severe Psoriasis: Long-Term Results from the UNCOVER-1 and UNCOVER-2 Phase-3 Randomized Controlled Trials
por: Leonardi, Craig, et al.
Publicado: (2020)

US Perspectives in the Management of Psoriasis and Psoriatic Arthritis: Patient and Physician Results from the Population-Based Multinational Assessment of Psoriasis and Psoriatic Arthritis (MAPP) Survey
por: Lebwohl, Mark G., et al.
Publicado: (2015)

Patient Characteristics, Health Care Resource Utilization, and Costs Associated with Treatment-Regimen Failure with Biologics in the Treatment of Psoriasis
por: A. Foster, Shonda, et al.
Publicado: (2016)

Cost per cumulative clinical benefit of biologic therapies for patients with plaque psoriasis: a systematic review
por: Blauvelt, Andrew, et al.
Publicado: (2021)

Ocular Manifestations in Psoriasis Screening (OcMaPS) Questionnaire: A Useful Tool to Reveal Misdiagnosed Ocular Involvement in Psoriasis
por: Ruggiero, Angelo, et al.
Publicado: (2021)

Development and Content Validation of the Psoriasis Symptoms and Impacts Measure (P-SIM) for Assessment of Plaque Psoriasis
por: Gottlieb, Alice B., et al.
Publicado: (2020)

Pregnancy Outcomes in Women With Moderate-to-Severe Psoriasis From the Psoriasis Longitudinal Assessment and Registry (PSOLAR)
por: Kimball, Alexa B., et al.
Publicado: (2021)

Treatment Persistence of Ixekizumab in Adults with Moderate-to-Severe Plaque Psoriasis Participating in the Canadian Patient Support Program
por: Gulliver, Wayne, et al.
Publicado: (2022)

Assessment of cardiac and vessel functions in childhood psoriasis
por: ŞAYLAN ÇEVİK, Berna, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_nr5b6esefi8bikvtuki1dhj146